The copper-binding peptide famous for regenerating aged skin, thickening hair, and accelerating wound healing — used topically or injected.
GHK-Cu is a naturally occurring tripeptide-copper complex (Glycyl-L-Histidyl-L-Lysine bound to a copper ion). It exists in human plasma, saliva, and urine, and its levels decline significantly with age — from around 200 ng/mL at age 20 to 80 ng/mL by age 60.
Extensive literature spans 50+ years; most foundational work is from the Pickart group, with independent replication of topical, wound-healing, and gene-expression findings. Topical GHK-Cu has a strong cosmetic safety profile (CIR 2014/2018, "safe in present practices of use and concentration" at <10 ppm); injectable safety is community-reported only — see Side Effects.
GHK-Cu is sold as a cosmetic ingredient (INCI: Copper Tripeptide-1) under CIR 2014/2018 "safe as used" coverage at typical concentrations <10 ppm. Injectable GHK-Cu is not FDA-approved for any indication; in April 2026 FDA removed it from the compounding "significant safety risks" category, and a Pharmacy Compounding Advisory Committee meeting in February 2027 will consider whether to add GHK-Cu to the §503A bulks list. Not currently named on the WADA 2026 Prohibited List, though broad categories (S2.5, S0) may apply at WADA's discretion.
In a 2018 microarray review (Pickart & Margolina, Int J Mol Sci, PMID 29986520) querying the Broad Institute Connectivity Map database, GHK altered expression of ~31% of CMap-assayed genes (~4,000 of ~12,800) in cultured fibroblasts at supraphysiologic concentration. The shifts moved expression toward patterns characteristic of younger cells — but this is in-vitro fibroblast data, not whole-organism in-vivo gene regulation, and has not been demonstrated in humans.
Copper is a cofactor for lysyl oxidase (collagen crosslinking) and superoxide dismutase (antioxidant defense). GHK shuttles copper into cells without the toxicity of free copper, exchanging Cu(II) with the high-affinity copper-binding site on serum albumin (Pickart 2008, PMID 18644225). The in-vivo flux is inferred from albumin-binding affinity comparisons, not directly measured in humans.
Stimulates fibroblasts to produce collagen, elastin, and glycosaminoglycans — the building blocks of firm, elastic, hydrated skin.
Reduces oxidative stress, quenches free radicals, and lowers pro-inflammatory cytokines. Translates to less UV damage, clearer skin, and reduced wound inflammation.
In dermal-papilla-cell and animal models, GHK-Cu enlarges hair follicles, extends the anagen growth phase, and upregulates VEGF/bFGF (mechanism). Pivotal-trial-quality human data for androgenetic alopecia is limited — see Research.
Well-documented in both dermatology and regenerative-medicine literature. Topical GHK-Cu is used in FDA-registered cosmetic products; injectable use is newer.
| Benefit | Evidence |
|---|---|
| Skin regeneration | 8–12-week topical RCTs show reduced wrinkles, improved firmness and thickness, better hydration (Pickart 2015 review, PMID 26236730 collates topical clinical evidence). Effects are smaller-magnitude than tretinoin and most published studies are industry-sponsored. |
| Hair regrowth | In dermal-papilla-cell and animal models, increases follicle count and hair-shaft diameter (mechanism). Topical clinical data exists primarily for post-transplant graft healing (GraftCyte) and small industry-sponsored AGA studies — no pivotal-trial-quality data comparable to finasteride or minoxidil. |
| Wound healing | Mulder 1994 (PMID 17147644): Iamin Gel diabetic-ulcer trial, 98.5% area closure vs 60.8% vehicle. Used historically in wound-care formulations; Iamin Gel did not progress to FDA drug approval. |
| Anti-aging gene expression (in vitro) | In cultured fibroblasts (Connectivity Map analysis), GHK altered expression of ~31% of assayed genes — ~4,000 of ~12,800 — with shifts toward expression patterns characteristic of younger cells (Pickart & Margolina 2018, PMID 29986520). The original CMap-based emphysema-reversal signature (127 genes) is in Campbell et al. 2012 Genome Medicine (PMID 22937864). Both are in-vitro datasets, not in-vivo whole-organism findings. |
| Scar reduction | Improves appearance of scars; reduces hypertrophic scar formation |
| Nerve regeneration | Preclinical data for peripheral nerve repair |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo human PK or RCT data exists for injectable GHK-Cu. The doses below are derived from community practice and animal-model extrapolation, not validated clinical recommendations.
Topical is safer and widely available, but keep in mind GHK-Cu is a fairly hydrophilic molecule with limited passive permeation through the lipophilic stratum corneum (PMID 39795193); delivery vehicles (liposomes, nanoparticles, microneedling) significantly affect how much actually reaches the dermis. Topical and injectable are not strictly equivalent — injectable likely achieves meaningfully higher dermal and systemic concentrations. Injectable is more commonly used for hair and systemic effects.
Topical application of 2–5% GHK-Cu solution directly to the scalp, 1–2× daily. Often combined with minoxidil, dermarolling, or finasteride empirically (mechanistic plausibility — different pathway targets — but no published combination RCT).
GHK-Cu injectable comes as a lyophilized blue-tinted powder (copper gives it color). Reconstitute with bacteriostatic water.
50 mg vial + 2 mL BAC water = 25 mg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 1 mg | 0.04 mL | 4 units |
| 2 mg | 0.08 mL | 8 units |
| 3 mg | 0.12 mL | 12 units |
50 mg vial at 2 mg/day = 25 days
Pre-filled with a typical GHK-Cu setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Topical GHK-Cu has a strong cosmetic safety profile (CIR 2014/2018, "safe in present practices of use and concentration" at <10 ppm). Injectable safety is community-reported only — the human injectable safety database is small and uncontrolled.
Topical or injectable?
For skin: topical is simpler, cheaper, and very effective. For hair: topical at the scalp. For systemic regeneration and wound healing: injectable.
How fast do I see skin results?
Hydration and texture within 2–4 weeks. Fine lines and firmness by 8–12 weeks. Deeper wrinkles and sun damage improve over 6+ months.
Why is it blue?
The copper (II) ion gives the solution a deep blue color. Color loss may suggest copper dissociation, but GHK–Cu2+ binding is an equilibrium (similar affinity to the copper transport site on albumin, PMID 18644225) — fading alone is not a validated stability assay. Follow manufacturer expiry over color; significant color loss is a conservative reason to discard, not proof of inactivity.
Can I stack GHK-Cu with BPC-157 or TB-500?
Yes — GHK-Cu complements both by providing the copper cofactor needed for collagen crosslinking during tissue repair.
Looking for GHK-Cu? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo injectable GHK-Cu is FDA approved for any indication. GHK-Cu (tripeptide-1) appears in many FDA-regulated cosmetic and topical skincare products and is generally recognized as safe for those uses by the Cosmetic Ingredient Review (CIR). The injectable form sold by peptide vendors is a research chemical with no human RCT, no published human PK study, and no regulatory authorization for systemic use.
The Cu(II) coordinated by the GHK peptide absorbs in the orange-red part of the visible spectrum (λmax ~525 nm), giving the complex a deep blue, blue-green, or teal color. Lyophilized powder is pale blue; reconstituted at 10 mg/mL it should be clearly blue. A CLEAR or colorless GHK-Cu solution is a red flag — either the product is mislabeled (free GHK without copper, or a different peptide entirely), or the copper has dissociated.
Community-practice injectable dosing is 1–3 mg/day subcutaneously, daily or 3–5 times per week, in 4–8 week cycles. These figures come from vendor education and forum convention — there is no peer-reviewed human dose-finding study for injectable GHK-Cu. Topical cosmetic doses are an entirely separate, much-better-studied use case at lower concentrations.
A typical reconstitution is 50 mg of GHK-Cu + 5 mL of bacteriostatic water, yielding 10 mg/mL. A 1 mg dose draws to 0.10 mL (10 units on a 100-unit insulin syringe). The solution should be clearly blue immediately after reconstitution — that color is your confirmation the copper is bound correctly.
People with Wilson’s disease (ATP7B mutation — autosomal-recessive copper-accumulation disorder) absolutely should not use any exogenous copper, including GHK-Cu. Same goes for other copper-dysregulation states: cholestatic liver disease, primary biliary cholangitis, and anyone on copper-chelating therapy (penicillamine, trientine) or zinc maintenance therapy for Wilson’s. Adding GHK-Cu in these contexts is contraindicated.
For cosmetic use (skin firmness, wrinkles, hair density), topical has a much larger published evidence base, an established safety profile, and is the route used in clinical and CIR-reviewed cosmetic studies. Injection produces higher dermal and systemic concentrations but the human evidence base for systemic effects is essentially absent. Most users treat injectable as the experimental route and topical as the validated one.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.